Celcuity Stock Rises on Launch of First Commercial Product
On Wednesday, Celcuity (NASDAQ: CELC) saw its stock rise by 2.8% despite a broader market decline that included the S&P 500 falling by 0.3%. The increase was driven by the company's announcement that it has launched Revtorpyk, its first FDA-approved drug for certain forms of breast cancer. Revtorpyk received regulatory approval in July and is now available to eligible patients across the U.S. Celcuity also introduced a support program offering financial assistance and other services to physicians and patients using the treatment. The company highlighted that HR+/HER2-negative breast cancer, which Revtorpyk targets, accounts for about 70% of all breast cancer cases globally. The market now awaits how well Revtorpyk will perform commercially. While much of the news had already been priced into the stock, investors remain optimistic due to the drug's potential in a large and growing patient population.
Tickers: $CELC
Topics: Biotech Cancer Treatment Commercialization FDA Approval